Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

ASCO® 2024 Summary: "Insights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

O. Hamid

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcome…

2024 ASCO® Annual Meeting Insights Hub

H. Tawbi

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in St…

2024 ASCO® Annual Meeting Insights Hub

A. Hauschild

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Vanderbilt University Medical Center (VUMC)

D. Johnson

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We Been a…

2024 ASCO® Annual Meeting Insights Hub

P. Corrie

History of Cancer and Its Treatment: What Will It Take to Cure?

University of Colorado Cancer Center

C. Lieu

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macro…

2024 ASCO® Annual Meeting Insights Hub

C. Blank

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment for…

Alexander van Akkooi